A Study of Remimazolam Tosilate for Sedation in the ICU

Inclusion criteria

• Patients and/or their guardians are able to provide a written informed consent, understand and agree to comply with the study requirements and protocol.
• Subjects have been treated with endotracheal intubation and mechanical ventilation, and are expected to receive sedation after randomization at least 6 hours. The target sedation level during the period is -2 ≤ RASS ≤ +1.
• 18 years to 80 years old, male or female.
• 18 kg/m2 ≤ BMI ≤ 30 kg/m2.

Exclusion criteria

• Deep sedation is required, or continuous sedation is not needed during the study process.
• Participants (other than in endotracheal intubation) who are expected to require neuro-muscle blockers during sedation.
• History of epilepsy or status epilepticus.
• Myasthenia gravis or a history of myasthenia gravis.
• Severe arrhythmias or heart disease; the circulatory system is unstable.
• Subjects with a history of severe cardiovascular disease, or cerebrovascular disease, or neurological disease, or mental illness.
• Subjects with a history of drug abuse.
• Organ failure before randomization.
• Abnormal values of the laboratory examination.
• Allergic to relevant drugs ingredient or component.
• Pregnant or nursing women.
• Subjects who has participated in clinical trials of other interventions recently.
• Other conditions deemed unsuitable to be included.